Cholera - Pipeline Review, H2 2017,
provides an overview of the Cholera (Infectious Disease) pipeline landscape.
Cholera is an acute infectious disease
caused by a bacterium, Vibrio cholera, which results in a painless, watery
diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as
long as five days after infection. Often symptoms are mild. But sometimes they
are very serious. Signs and symptoms of Cholera include rapid heart rate, loss
of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated,
this can lead to shock and death in a matter of hours.
Report
Highlights
Cholera - Pipeline Review, H2 2017,
provides comprehensive information on the therapeutics under development for
Cholera (Infectious Disease), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases.
The Cholera (Infectious Disease) pipeline
guide also reviews of key players involved in therapeutic development for
Cholera and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Phase II, Phase I and Preclinical stages
are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II,
Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules,
respectively.
Cholera (Infectious Disease) pipeline guide
helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built using data
and information sourced from Publisher’s proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)
Reasons
to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 43 pages “Cholera
- Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Cholera
- Overview, Cholera - Therapeutics Development, Cholera - Therapeutics
Assessment, Cholera - Companies Involved in Therapeutics Development, Cholera -
Dormant Projects, Appendix. This report Covered Companies - Akthelia
Pharmaceuticals Ltd, Beijing Minhai Biotechnology Co Ltd, Napo Pharmaceuticals
Inc.
Please visit this link for more details: http://mrr.cm/Upw
Find all Pharma
and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
Related
Reports;
Erectile Dysfunction - Pipeline Review, H2
2017 - Visit at - http://mrr.cm/UqA
Diabetic Macular Edema - Pipeline Review,
H2 2017 - Visit at - http://mrr.cm/UqG
No comments:
Post a Comment
Note: only a member of this blog may post a comment.